Research programme: small molecule therapeutics - Nuevolution
Latest Information Update: 13 Oct 2015
At a glance
- Originator The Scripps Research Institute
- Developer Nuevolution
- Class Small molecules
- Mechanism of Action Integrin alphaVbeta3 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer